Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q3 revenue and earnings exceeded estimates, with EPS of $1.34 versus $1.21 expected and margin expansion across all segments. Shares gained 16.3% over 21 days, including a 6.9% rise on October 28.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Durable Margins ⢠Weak Cash Conversion ⢠Elevated Leverage GE HealthCare offers durable margins and moderate valuation, but declining liquidity, weak recent cash conversion, and high leverage/intangibles warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Persistent selling ⢠Critical support ⢠Oversold rebound Support Level: $63.50â$64.00 Resistance Level: $65.15â$66.80 GEHC remains in a last-month downtrend, with $63.50â$64.00 support critical and a rebound needing a sustained move above $65.15â$66.80.
Sentiment & News
Key News Insights: ⢠Record Backlog ⢠Ultrasound Expansion ⢠Legal Overhang GE HealthCare's strong orders, backlog, product innovation, and institutional buying support growth visibility, but margin, debt, and securities-investigation risks remain key overhangs.
AI Summary
GEHC's investment case hinges on converting its $23.9B backlog and premium imaging/AI offerings into revenue growth above its 3%â4% outlook and materially stronger free-cash-flow conversion; the current valuation is reasonable, but not low enough to absorb another execution miss. Investors should wait for evidence of improving backlog conversion, margins, and cash generationâparticularly amid PCS weakness and reduced liquidityâbefore treating the oversold share price as a durable buying opportunity.
Description
GE HealthCare Technologies develops, manufactures and sells medical devices, diagnostic agents and supporting digital solutions for use in patient diagnosis, treatment and monitoring across North America, Europe, Asia and other markets. Organized into four segmentsâImaging, Ultrasound, Patient Care Solutions and Pharmaceutical Diagnosticsâthe company supplies imaging systems (including CT, MR and molecular imaging), point-of-care and surgical ultrasound, bedside monitoring and therapeutic devices, and contrast media and radiopharmaceuticals. Incorporated in 2022, it is headquartered in Chicago, Illinois.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Oct 28 | Nov 4 | GEHC | GE HealthCare Technologies Inc. | Q3 revenue and earnings exceeded estimates, with EPS of $1.34 versus $1.21 expected and margin expansion across all segments. Shares gained 16.3% over 21 days, including a 6.9% rise on October 28. | Active | +0.0% |
| Jul 30 | Aug 6 | GEHC | GE HealthCare Technologies Inc. | Constructive healthcare setup after Q2 2026 beat EPS and revenue expectations, with record orders, record backlog, and growth across every segment. Commercial catalysts include a $500M Catholic Health partnership and FDA clearance for MIM Contour ProtegeAI+ 2.0. | Closed | +0.5% |